1 / 28

Botulinum Toxin in Post-Stroke Spasticity

Botulinum Toxin in Post-Stroke Spasticity. 19/05/03 Craig Douglas. Spasticity. Overactivity in the muscles following damage to the brain or spinal cord Causes pain and deformity Decreases independence Increases post stroke complications

Mia_John
Download Presentation

Botulinum Toxin in Post-Stroke Spasticity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Botulinum Toxin in Post-Stroke Spasticity 19/05/03 Craig Douglas

  2. Spasticity • Overactivity in the muscles following damage to the brain or spinal cord • Causes pain and deformity • Decreases independence • Increases post stroke complications • Treatment may involve a combination of physio, antispasmodic drugs, BT and surgery

  3. Botulinum Toxin • BT neurotoxin binds with H chain to the BT receptor at the cholinergic nerve ending • L chain then transported into the nerve ending, where it blocks the transport of molecules mediating the transport of Ach to the synapse • L chains also cleave SNARE proteins, preventing membrane formation for Ach transport • Action is terminated by axonal sprouting of the peripheral nerve (takes 12 weeks)

  4. BT- Mechanism of Action

  5. Botulinum Toxin • Objective of therapy is to decrease dystonic strength as much as possible • However, BT has same effects on voluntary strength • Voluntary Strength = FS + RS • For BT to be effective, FS must be preserved

  6. BT – Therapeutic Goals • Patient Care Indications -Goals are expected decreases in staffing requirements, caring time and resource consumption • Therapeutic Indications -Goals are increasing patient’s independency and decreasing pain

  7. BT – Favourable Prognosis • Focal spasticity • No connective tissue involvement • Realistic goals • Relatively good power (BMRC >2) • Voluntary activity • Absence of psychological or mental impairment • Good motivation

  8. BT – Available Preparations • BOTOX and Dysport -Neurotoxin per vial: BOTOX = 4.8 ng Dysport = 12.5 ng -Adverse Reactions: BOTOX = 15% Dysport = 26%

  9. BT – Clinical Info • Clinical improvement after 2 weeks • Peak effects after 4-6 weeks • Contraindications: -MG, aminoglycosides, bleeding disorders, pregnancy and lactation • Adverse Reactions: -Purpura, arm pain, muscle weakness, hypertonia • No known transmission of HIV or Hep.

  10. BT – Clinical Info • BOTOX – max. dose 400-500 units • 1 injection site for strap-like muscles • Multiple injection sites for flat/pennate muscles • May use EMG to help locate injection site • Therapeutic doses – too low to produce immune response • Macromolecule, mol wt 150 kDa, blood-brain barrier is not crossed

  11. Other Options!

  12. Local Treatments Local anaesthetics Ethyl alcohol Phenol

  13. Local Anaesthetics • Lidocaine, etidocaine or bupivocaine • Decrease/prevent the large transient increase in membrane permeability to Na ions • Reversible • Act within minutes, but effects only last hours!

  14. Local Anaesthetics – Risks! • If drug enters systemic circulation, it interferes with the function of all organs where impulse conduction occurs • CNS effects- tremor, convulsions • May cause hypotension and inhibit cardiovascular reflexes • Allergic responses • Never use in hepatic dysfunction!

  15. Ethyl Alcohol • At low conc. (5-10%), it acts as a local anaesthetic by decreasing Na and K conductance • At higher conc. (30-50%), it acts as a hypobaric compound that denatures proteins and damages cells

  16. Ethyl Alcohol – Risks! • Burning pain at site of injections • Local Hyperaemia (Carpenter et al) • Phlebitis (O’Hanlon et al) • Temporary sensory defecit

  17. Phenol • Phenol is a derivative of benzene • It works by non-selectively denaturing proteins and causing tissue necrosis • May cause occlusion of small blood vessels and fibrosis in the injected area

  18. Phenol – Risks! • Tendency to cause pain • Chronic dysaesthesiae (2-32%) • Peripheral oedema • DVT • Local infection due to bacteriocidal properties • Tremor and convulsions

  19. Advantages: early onset action low cost better stability Disadvantages: lack of selectivity tissue destruction propensity to pain lots of SE’s Alcohol and Phenol

  20. General Treatments Baclofen Benzodiazepines Dantrolene

  21. Baclofen • Structural analogue of GABA • Rapid absorption, and half life of two to six hours • Binds to GABAb receptors pre and post synaptically, causing membrane hyperpolarisation and a decrease in endogenous transmitter release • Excreted by kidneys (unchanged)

  22. Baclofen – Side Effects! • Sedation and fatigue • Confusion, N&V in brain injury!!! -Hulme et al, Eur Journal of Clin Pharm, 1985 Trial stopped due to unacceptable levels of the above side effects in elderly stroke patients • Increase bronchoconstriction • May cause ataxia and paraesthesiae • May cause memory loss (animal stu)

  23. Benzodiazepines • These drugs work at the GABAa receptor • Increase presynaptic inhibition • Duration of action is related to metabolism of parent compound • Side Effects: -Depression of CNS, synergistic with alcohol A decrease in alertness, memory, co-ordination Deterioration of ability to walk and grip strength

  24. Dantrolene • Unique • Acts at muscle fibre rather than at the neural level • Decreases muscle AP induced release of Ca from the SR, THEREFORE, partial uncoupling of motor nerve excitation and muscle contraction develops

  25. Dantrolene – Sde Effects! • Sedating • Nausea and vomiting • Slurred speech, dizziness, diarrhoea and paraesthesiae • Hepatotoxicity – 2% of patients

More Related